G2-PASE a reliable measure of psoriasis severity

[Fred]

In this cross-sectional analysis of a large, real-world Canadian cohort, G2-PASE demonstrated very strong correlation and excellent reliability compared with PASI.

Quote:

---

Background:
The Psoriasis Area and Severity Index (PASI), a composite measure of plaque psoriasis disease severity, is commonly used to determine treatment eligibility and response, but is time consuming for every-day clinical use. The Gulliver-Gestalt-Psoriasis Area Severity Estimate (G2-PASE) was developed to approximate PASI scores using Physician Global Assessment (PGA) and body surface area (BSA) measures.

Objectives:
To determine the reliability and validity of G2-PASE compared to PASI using data from a multi-center, Canadian cohort of patients with plaque psoriasis.

Methods:
Canadian patients with a history of moderate to severe plaque psoriasis enrolled in the first cohort of the Psoriasis Longitudinal Assessment and Registry (PSOLAR 1; a global, prospective, longitudinal, disease-based registry) were included. The G2-PASE for each patient was calculated by applying baseline PGA and BSA values available from PSOLAR patient data at enrollment. The correlation and reliability of G2-PASE compared to PASI for each patient at enrollment was then assessed. A similar analysis was conducted to test the reproducibility of results previously published by a participating PSOLAR clinical trial site.

Results:
Of the 1896 Canadian patients in PSOLAR 1, 1803 had PASI data and were included in this analysis. The average baseline PASI score was 5.52 (SD 6.44, range 0.00–64.30), and the mean calculated G2-PASE score was 8.37 (SD 7.51, range 0.00–45.00). The Pearson's correlation coefficient was 0.83 (p < 0.0001), indicating very strong and significant correlation between PASI and G2-PASE scores. The standardized Cronbach coefficient alpha was 0.91. Results from the Canadian PSOLAR cohort are similar to those of patients enrolled at the New Lab Clinical Research Inc. site and complement findings previously reported from this site.

Conclusions:
This study validates G2-PASE as a reliable measure of plaque psoriasis severity when compared to PASI among a large cohort of patients with predominantly moderate to severe disease.

Source: onlinelibrary.wiley.com

*Funding: Janssen

What is the PASI score my dermatologist uses ?

NO LINKS ALLOWED

[Caroline]

I will give a longer comment later on…

But for now… I think it is slightly hilarious to choose a number between 0 and 6…. And call that a “tool”.



Even a hammer is more complex… 

———

Okay. So this “Gulliver-Gestalt-Psoriasis Area Severity Estimate (G2-PASE)”, carries a heavy name, but in fact it is an intuitive estimate of the severity of the Psoriasis on a 0-6 scale.
Combined with the BSA measure of the area that is affected on the basis of the handpalm, where each handpalm stands for 1%.. (so if you have big hands, you are lucky as you then have less psoriasis.. )

Personally I can’t view this as a “Tool” as this suggests scientific accuracy, which is certainly not an aspect of this method.
Anyway we can see that the normal PASI score is way more accurate.. and let’s be realistic… how difficult is it to fill in the PASI-score? It is amazingly simple.

The, for me idiotic and far overrated, point is that all those “measurements” PASI, BSA, SAPASI, PEST, PRIDD, etcetera are so called (I have done some research) validated “tools” () which means that they are developed by professional medics and are all copyrighted so you cannot use them only if you are a professional or otherwise you need some consent and maybe even may have to pay a fee…
And that for sometimes very easy and obvious question lists…